Development of a Personalized Pharmacologic Treatment Repository for Bronchial Asthma Based on the 2018 Guideline for the Diagnosis and Management of Bronchial Asthma in Primary Care（Practice Edition）

Abstract

Bronchial asthma is a chronic inflammatory disease with high heterogeneity, polygenic inheritance, complex etiology and many complications. The effects of prevention and treatment for a bronchial asthma patient often depend on whether the patient has received a personalized health management. In order to be in line with the international management level of bronchial asthma, the updates in the 2018 Guideline for the Diagnosis and Management of Bronchial Asthma in Primary Care (Practice Edition, here in after referred to as the 2018 Guideline) contain the idea of early intervention, optimized medication regimens, and highlighted standardized management approach regarding bronchial asthma. To promote personalized pharmacologic management of bronchial asthma in primary care, and to provide online pre-, mid- and post-diagnosis pharmaceutical services for physicians, as well as personalized pharmacologic monitoring and management services for bronchial asthma patients in the community, pharmacists have developed a search engine with integrated functions of "pre-judgment, early warning and prediction" to collect medication information related to bronchial asthma using the information technology, according to the pharmacologic treatment path "initial treatment, long-term treatment, degradation principle" put forward in the 2018 Guideline, with the "one factory, one drug, one specification" individualized instruction as a basis.

Keywords

• |bronchial asthma|guideline|antiasthmatic medication|knowledge base|personalized|intelligent